Care was less costly compared to pregabalin and lidocaine.
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OBJECTIVE:
The objective of this analysis was to estimate and compare the annual cost per patient of the administration of capsaicin 8% patch, Qutenza ® , in Primary and Secondary Care for the treatment of adult patients with peripheral neuropathic pain (PNP). The annual cost per patient treated with Qutenza ® was also compared to pregabalin and lidocaine in Primary Care.
METHODS:
The costs per patient for each treatment were estimated by analysing the healthcare resources associated with the use of pregabalin, lidocaine and Qutenza ® for the treatment of PNP from the perspective of the Spanish National Health System. Healthcare resources associated with the three pharmacological treatments were administration time and healthcare personnel, complementary non-pharmacological treatment, hospitalisation, adverse effects and concomitant medication (EUR 2013) . Total costs per patient were estimated including concomitant medication to estimate the effect on the treatment costs.
RESULTS:
The annual treatment cost per patient when Qutenza ® is administrated in the hospital was estimated at €5,387.32 and €5,259.19 when administered in Primary Care. Qutenza ® applied in Primary Care for the treatment of PNP showed annual savings of €128.14 per patient compared with the administration of Qutenza ® in Secondary Care. Overall, the annual treatment costs per patient with pregabalin or lidocaine were estimated at €14,074.14 and € 5,998.09, respectively, resulting in savings of €8,814.95 and €738.9 respectively when compared with the annual cost per patient when treated with Qutenza ® in Primary Care.
CONCLUSIONS:
The introduction of Qutenza ® into Primary Care for the treatment of PNP is expected to result in annual savings due to lower administration costs associated with the use of Qutenza ® and savings in healthcare personnel in Primary Care. Qutenza ® also showed to be the less expensive option in comparison with pregabalin or lidocaine, independent of the area of administration.
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